Checkpoint Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Additional Information (Details)

Stockholders' Equity - Additional Information (Details)		1 Months Ended				3 Months Ended		9 Months Ended
Stockholders' Equity - Additional Information (Details)	Jan. 01, 2023 shares	Jul. 31, 2023 USD ($) $ / shares shares	May 31, 2023 USD ($) $ / shares shares	Apr. 30, 2023 USD ($) $ / shares shares	Feb. 28, 2023 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) Vote multiplier $ / shares shares	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) Vote multiplier $ / shares shares	Sep. 30, 2022 USD ($)	Jun. 12, 2023 $ / shares shares	Mar. 31, 2023 USD ($)	Feb. 22, 2023 $ / shares	Dec. 31, 2022 $ / shares shares	Dec. 16, 2022 $ / shares	Nov. 03, 2022 shares	Nov. 30, 2020 USD ($)
Stockholders' Equity
Common stock, increase in the number of authorized shares (in shares)										30,000,000
Common stock, shares authorized						80,000,000		80,000,000		80,000,000			50,000,000
Common stock, par value (in dollars per share) \| $ / shares						$ 0.0001		$ 0.0001		$ 0.0001			$ 0.0001
Common stock, shares outstanding						21,702,547		21,702,547					9,586,683
Number of votes per share \| Vote						1		1
Multiplier to calculate voting rights per class A common share \| multiplier						1.1		1.1
Number of non assessable shares issued upon conversion						1		1
Shelf registration statement, maximum authorized securities \| $																$ 100,000,000
Issuance of common shares - Founders agreement \| $						$ 251,000	$ 26,000	$ 809,000	$ 239,000
Class of warrants exercise price \| $ / shares												$ 5.00		$ 4.075
Pre-Funded Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares		809,062
Class of warrants exercise price \| $ / shares		$ 3.0899
Series A Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares		3,236,248
Class of warrants exercise price \| $ / shares		$ 2.84
Series B Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares		3,236,248
Non-vested restricted stock
Stockholders' Equity
Total unrecognized compensation cost related to non-vested \| $						$ 3,000,000.0		$ 3,000,000.0
Weighted average period (in years)								1 year 10 months 24 days
Performance Shares
Stockholders' Equity
Restricted stock outstanding non-vested						196,733		196,733
2015 Incentive Plan
Stockholders' Equity
Number of shares available for issuance authorized						6,000,000		6,000,000
Plans expires (in years)								10 years
Shares are available for issuance						3,496,830		3,496,830
Maximum \| 2015 Incentive Plan
Stockholders' Equity
Number of shares available for issuance authorized															3,000,000
Minimum \| 2015 Incentive Plan
Stockholders' Equity
Number of shares available for issuance authorized															900,000
At the market offering (ATM)
Stockholders' Equity
Total gross proceeds from Issuance of common stock \| $									9,939,000
Amount of commissions and other transaction costs \| $									$ 244,000
February 2023 Registered Direct Offering
Stockholders' Equity
Purchase price per share \| $ / shares					$ 5.25
Number of shares issued and sold					1,180,000
Total gross proceeds from Issuance of common stock \| $					$ 7,500,000
Net proceeds from offering \| $					6,700,000
Amount of commissions and other transaction costs \| $					$ 800,000
February 2023 Registered Direct Offering \| Pre-Funded Warrants
Stockholders' Equity
Number of warrants issued					248,572
Class of warrants exercise price \| $ / shares					$ 5.2499
February 2023 Registered Direct Offering \| Series A Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares					1,428,572
Class of warrants exercise price \| $ / shares					$ 5.00
Expiration term of warrants (in years)					5 years
February 2023 Registered Direct Offering \| Series B Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares					1,428,572
Class of warrants exercise price \| $ / shares					$ 5.00
Expiration term of warrants (in years)					18 months
February 2023 Registered Direct Offering \| Maximum \| Series A Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares					1,428,572
February 2023 Registered Direct Offering \| Maximum \| Series B Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares					1,428,572
April 2023 Direct Offering
Stockholders' Equity
Purchase price per share \| $ / shares				$ 3.60
Shelf registration statement remaining authorized securities \| $						$ 8,700,000		$ 8,700,000			$ 150,000,000
Number of shares issued and sold				1,700,000
Total gross proceeds from Issuance of common stock \| $				$ 6,100,000
Net proceeds from offering \| $				5,500,000
Amount of commissions and other transaction costs \| $				$ 600,000
April 2023 Direct Offering \| Series A Warrants
Stockholders' Equity
Class of warrants exercise price \| $ / shares				$ 3.35
Expiration term of warrants (in years)				5 years
April 2023 Direct Offering \| Series B Warrants
Stockholders' Equity
Class of warrants exercise price \| $ / shares				$ 3.35
Expiration term of warrants (in years)				18 months
April 2023 Direct Offering \| Maximum \| Series A Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares				1,700,000
April 2023 Direct Offering \| Maximum \| Series B Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares				1,700,000
May 2023 Registered Direct Offering
Stockholders' Equity
Purchase price per share \| $ / shares			$ 3.071
Number of shares issued and sold			1,650,000
Number of warrants issued			1,606,269
Class of warrants exercise price \| $ / shares			$ 3.0709
Total gross proceeds from Issuance of common stock \| $			$ 10,000,000.0
Net proceeds from offering \| $			9,100,000
Amount of commissions and other transaction costs \| $			$ 900,000
May 2023 Registered Direct Offering \| Pre-Funded Warrants
Stockholders' Equity
Number of warrants issued			1,606,269
Class of warrants exercise price \| $ / shares			$ 3.0709
May 2023 Registered Direct Offering \| Series A Warrants
Stockholders' Equity
Class of warrants exercise price \| $ / shares			$ 2.821
Expiration term of warrants (in years)			5 years
May 2023 Registered Direct Offering \| Series B Warrants
Stockholders' Equity
Class of warrants exercise price \| $ / shares			$ 2.821
Expiration term of warrants (in years)			18 months
May 2023 Registered Direct Offering \| Maximum \| Series A Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares			3,256,269
May 2023 Registered Direct Offering \| Maximum \| Series B Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares			3,256,269
July 2023 Registered Direct Offering
Stockholders' Equity
Purchase price per share \| $ / shares		$ 3.09
Number of shares issued and sold		2,427,186
Total gross proceeds from Issuance of common stock \| $		$ 10,000,000.0
Net proceeds from offering \| $		9,100,000
Amount of commissions and other transaction costs \| $		$ 900,000
July 2023 Registered Direct Offering \| Pre-Funded Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares		809,062
Class of warrants exercise price \| $ / shares		$ 3.0899
July 2023 Registered Direct Offering \| Series A Warrants
Stockholders' Equity
Class of warrants exercise price \| $ / shares		$ 2.84
Expiration term of warrants (in years)		5 years
July 2023 Registered Direct Offering \| Series B Warrants
Stockholders' Equity
Class of warrants exercise price \| $ / shares		$ 2.84
Expiration term of warrants (in years)		18 months
July 2023 Registered Direct Offering \| Maximum \| Series A Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares		3,236,248
July 2023 Registered Direct Offering \| Maximum \| Series B Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares		3,236,248
Fortress
Stockholders' Equity
Issuance of common shares - Founders agreement \| $								800,000
Shelf registration statement remaining authorized securities \| $						$ 91,700,000		$ 91,700,000
Percentage of annual equity fee	2.50%							2.50%
Number of shares issued and sold	368,907							240,526
Agent
Stockholders' Equity
Commission rate																3.00%
Common Stock
Stockholders' Equity
Number of shares issued and sold		2,427,186
Share price \| $ / shares		$ 3.09
Total gross proceeds from Issuance of common stock \| $		$ 10,000,000.0
Net proceeds from offering \| $		9,100,000
Amount of commissions and other transaction costs \| $		$ 900,000
Common Class A
Stockholders' Equity
Common stock, shares authorized										700,000
Common stock, shares outstanding						700,000		700,000					700,000